TIDMPOLB

Poolbeg Pharma PLC

21 October 2022

Poolbeg Pharma plc

Upcoming Events

21 October 2022 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, announces that its management and business development team will be attending and presenting at a number upcoming partnering and investor events from October 2022 to January 2023.

Partnering events

 
 --   BIO-Europe from 24-26 October 2022 at Leipzig Messe, Leipzig, 
       Germany 04356 
 --   Jefferies London Healthcare Conference from 15-17 November 2022 
       in London 
 --   JP Morgan 41(st) Annual Healthcare Conference from 9-12 January 
       2023 at the Westin St. Francis Hotel, San Francisco, CA

Investor events

 
 --   London South East Webinar (virtual) on 8 November 2022. Register 
       here 
 --   LSX InvEUR$tival Showcase(TM) on 14 November 2022 at Old Billingsgate, 
       London EC3R 6DX. Poolbeg CEO, Jeremy Skillington, will present 
       at 14:15 on Stage 4: Biotech Late Growth. Register here

Event details may be subject to change - further information and updates are available on the Poolbeg Pharma website here .

- Ends -

Enquiries

 
 Poolbeg Pharma Plc 
  Jeremy Skillington, CEO                   +44 (0) 20 7183 
  Ian O'Connell, CFO                         1499 
 finnCap Ltd (Nominated Adviser & Joint 
  Broker) 
  Geoff Nash, James Thompson, Charlie 
  Beeson 
  Nigel Birks, Harriet Ward (ECM)          +44 (0) 20 7220 0500 
 Singer Capital Markets (Joint Broker) 
  Phil Davies, Sam Butcher                 +44 (0) 20 7496 3000 
 J&E Davy (Joint Broker) 
  Anthony Farrell, Niall Gilchrist         +353 (0) 1 679 6363 
 Instinctif Partners                       +44 (0) 20 7457 2020 
  Melanie Toyne Sewell, Rozi Morris,        poolbeg@instinctif.com 
  Tim Field

About Poolbeg Pharma

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a unique capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a "one-stop shop" for pharma and biotech seeking mid-stage products to license or acquire.

The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.

With its initial assets from Open Orphan plc , an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza (POLB 001) which has commenced its LPS human challenge trial with initial results expected by year end 2022; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing an oral vaccine delivery platform and is progressing two artificial intelligence (AI) programmes to accelerate the power of its human challenge model data and biobank, with results from the first programme expected by year end 2022.

For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRADZMZGNGRGZZM

(END) Dow Jones Newswires

October 21, 2022 02:00 ET (06:00 GMT)

Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Poolbeg Pharma Charts.
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Poolbeg Pharma Charts.